Children malignant tumor treatment process and follow-up visit electronic management system and method

Abstract

The invention relates to the field of medical information management, in particular to a children malignant tumor treatment process and follow-up visit electronic management system and a children malignant tumor treatment process and follow-up visit electronic management method. The method comprises the steps that the body surface area of a patient is calculated, and the chemotherapy drug dosage in each cycle is calculated based on the body surface area of the patient; performing cycle-by-cycle accumulation on the chemotherapeutic drug dose in each cycle to obtain an actual accumulated dose; calculating and standardizing the specific numerical value of each curative effect index based on the actual accumulated dose, and calculating a comprehensive therapeutic effect score by combining the importance weight of each curative effect index; and calculating the disease-free survival rate based on the actual accumulated dose and the comprehensive treatment effect score. The problems that at present, most medicine dosage calculation methods neglect the special physiological features of children, a treatment monitoring system lacks dynamic adjustment support in the treatment process, a follow-up management system is insufficient in quantitative analysis capacity for long-term prognosis, and personalized long-term health management suggestions cannot be provided for patients are solved.

Description

Technical Field

[0001] The present invention relates to the field of medical information management, and in particular to an electronic management system and method for the treatment process and follow-up of childhood malignant tumors. Background Art

[0002] With the rapid development of medical information technology, the application of electronic management systems in the medical field has been gradually popularized, providing important support for the formulation of treatment plans, dynamic monitoring of treatment progress and long-term follow-up management. In tumor treatment, the combination of computer-based decision-making technology and personalized patient data analysis makes drug dosage calculation, treatment effect evaluation and prognosis prediction more accurate. At the same time, with the advancement of data storage and processing technology, the large amount of data generated during the treatment process can be efficiently collected, analyzed and converted into visual information, providing a powerful tool for doctors to optimize treatment decisions and patients to improve treatment compliance, providing a technical basis for the personalization and scientific treatment of childhood malignant tumors, and promoting the continuous improvement of treatment effects and survival rates.

[0003] However, the current electronic management system for pediatric tumor treatment has some limitations, such as ignoring the special physiological characteristics of children, and the difficulty of the treatment monitoring system in providing doctors with timely decision-making basis. Therefore, there is an urgent need for a technology that can effectively solve the above limitations to improve the electronic management system for pediatric tumor treatment. Summary of the invention

[0004] The present invention provides an electronic management system and method for the treatment process and follow-up of malignant tumors in children, so as to solve the problems that most current drug dosage calculation methods ignore the special physiological characteristics of children, such as differences in metabolic rate and drug distribution, resulting in possible deviations in drug dosage design, thereby increasing the risk of toxic and side effects or reducing efficacy; and that most treatment monitoring systems focus on the storage of static data and lack support for dynamic adjustments in the treatment process, such as monitoring of cumulative doses and real-time evaluation of efficacy scores, making it difficult to provide doctors with timely decision-making basis; and that the follow-up management system lacks the ability to quantify and analyze long-term prognosis, especially the dynamic prediction of important indicators such as disease-free survival rate is not perfect, and cannot provide patients with personalized long-term health management suggestions.

[0005] The electronic management system and method for the treatment process and follow-up of childhood malignant tumors of the present invention specifically include the following technical solutions: A method for electronic management of the treatment progress and follow-up of childhood malignant tumors, comprising the following steps: S1: Based on the basic information of the patient, the patient's body surface area is calculated; based on the standard chemotherapy drug dose set according to the patient's condition and the patient's body surface area, the chemotherapy drug dose for each cycle is calculated; the actual cumulative dose is obtained by accumulating the chemotherapy drug dose for each cycle cycle by cycle; S2: Based on the actual cumulative dose, calculate the specific value of each efficacy indicator; calculate the comprehensive treatment effect score by standardizing the specific value of each efficacy indicator and combining the importance weights of each efficacy indicator; calculate the disease-free survival rate based on the actual cumulative dose and the comprehensive treatment effect score.

[0006] Preferably, the S1 specifically includes: The age correction factor, gender correction factor and body fat percentage are introduced into the body surface area calculation formula. The specific formula is as follows: , in, is the patient's body surface area; is the constant for calculating body surface area; is the patient's height; is the patient's weight; is the age correction factor; is the patient’s actual age; is the gender correction factor; is gender, which is assigned a value based on the patient's gender, 1 for boys and 0 for girls; is the patient's body fat percentage; It is the standard body fat percentage.

[0007] Preferably, the S1 specifically includes: The standard chemotherapy drug dose is set, and the patient's liver function and heart function test data are obtained. The chemotherapy drug dose for each cycle is calculated by combining the patient's body surface area.

[0008] Preferably, the S1 specifically includes: The formula for calculating chemotherapy drug dosage per cycle is as follows: , in, is the chemotherapy drug dose per cycle; It is the standard chemotherapy drug dose, which indicates the drug dose required per square meter of body surface area; It is an index operation; is the patient's actual alanine aminotransferase value, derived from liver function test results; is a normal alanine aminotransferase value; Reflects the effect of liver function on drug metabolism; is the patient's left ventricular ejection fraction, derived from the results of cardiac function tests; is normal left ventricular ejection fraction; Reflects the impact of cardiac function on drug tolerance.

[0009] Preferably, the S1 specifically includes: Measuring treatment progress and total drug exposure through actual cumulative doses helps doctors evaluate the overall effectiveness of chemotherapy while monitoring whether there is a risk of toxicity caused by excessive drug doses; and adjusting treatment plans in a timely manner based on actual cumulative doses.

[0010] Preferably, the S2 specifically includes: The calculation formula of efficacy index is introduced, and the ratio of target cumulative dose to actual cumulative dose is combined to quantitatively evaluate the efficacy; the calculation formula of each efficacy index is as follows: , in, It is Specific values ​​of the efficacy indicators; is the index variable of the efficacy index; It is The ideal value of each efficacy indicator; It is the coefficient that adjusts the effect of dose deviation on efficacy, and its value range is 0 to 1; is the actual cumulative dose; is the target cumulative dose; It indicates the degree of deviation between the actual cumulative dose and the target cumulative dose.

[0011] Preferably, the S2 specifically includes: The disease-free survival rate was calculated based on the comprehensive treatment effect score, combined with the treatment delay time and follow-up data corresponding to the follow-up stage.

[0012] Preferably, the S2 specifically includes: The disease-free survival rate was calculated as follows: , in, is the disease-free survival rate; indicates the follow-up time; is the total number of follow-up periods; is the current follow-up phase number; Indicated in The number of adverse events that occurred during the follow-up period; is the treatment delay effect coefficient; is the treatment delay time, which represents the time difference between the ideal treatment time point and the actual treatment start time point; is the cumulative dose influence coefficient; It is The total number of patients in the follow-up period was obtained based on the follow-up data; It is the patient's comprehensive treatment effect score.

[0013] An electronic management system for the treatment process and follow-up of childhood malignant tumors, applied to the above-mentioned electronic management method for the treatment process and follow-up of childhood malignant tumors, includes the following parts: Patient information management module, body surface area calculation module, drug dosage calculation module, cumulative dosage calculation module, efficacy evaluation module, disease-free survival rate prediction module; The patient information management module is responsible for collecting the patient's basic information and related examination data, and receiving the output data of all modules except the patient information management module and the body surface area calculation module; the patient information management module stores the output data, related examination reports and follow-up data received from each module, and displays them in the form of trend charts or reports; the patient information management module is connected to the body surface area calculation module and the drug dosage calculation module by means of data transmission; The body surface area calculation module obtains the basic information of the patient from the patient information management module, calculates the patient's body surface area through the body surface area calculation formula and outputs it. The body surface area calculation module is connected with the drug dosage calculation module and the patient information management module by means of data transmission; The drug dosage calculation module receives the body surface area of ​​the patient output by the body surface area calculation module and the relevant examination data output by the patient information management module, including liver function test data and heart function test data, calculates and outputs the chemotherapy drug dosage for each cycle, and the drug dosage calculation module is connected to the patient information management module by means of data transmission; The cumulative dose calculation module receives the chemotherapy drug dose per cycle stored in the patient information management module, calculates the actual cumulative dose by accumulating it cycle by cycle, and outputs it. The cumulative dose calculation module is connected to the patient information management module by data transmission; The efficacy evaluation module receives the actual cumulative dose stored in the patient information management module, and calculates the specific value of each efficacy indicator in combination with the target cumulative dose and the type and number of efficacy indicators; normalizes the specific value of each efficacy indicator, and calculates and outputs the comprehensive treatment effect score according to the importance weight of each efficacy indicator. The efficacy evaluation module is connected to the patient information management module by data transmission; The disease-free survival rate prediction module obtains the actual cumulative dose, comprehensive treatment effect score and follow-up data corresponding to the current follow-up stage from the patient information management module, calculates the disease-free survival rate, and the disease-free survival rate prediction module is connected to the patient information management module by data transmission; The follow-up phase refers to the phase after treatment, during which the patient's health status, efficacy indicators, and survival status are regularly monitored to collect relevant data to evaluate the treatment effect and guide subsequent management; Follow-up data are patient health information collected during the follow-up phase, including efficacy indicators, cumulative doses, recurrences, and adverse events.

[0014] The beneficial effects of the technical solution of the present invention are: 1. The present invention incorporates factors such as age, gender and body fat percentage into the body surface area calculation formula, and combines the results of liver function and heart function tests to dynamically adjust the chemotherapy drug dosage in each cycle, fully considering the special physiological characteristics of metabolic rate and drug distribution of child patients; compared with the traditional simple scaling of adults or the doctor's experience judgment, the present invention significantly improves the scientific nature of drug dosage design, reduces the risk of toxic and side effects caused by dosage deviation, and at the same time ensures the stability of therapeutic effect, providing technical guarantee for precision treatment.

[0015] 2. Dynamic management of the treatment process is achieved by introducing the actual cumulative dose, specific values ​​of efficacy indicators and comprehensive treatment effect scores.

[0016] 3. The present invention combines the actual cumulative dose, comprehensive treatment effect score, treatment delay time and follow-up data to propose a method for dynamically predicting disease-free survival rate, which can quantify the probability that the patient will not experience disease progression or recurrence after treatment, significantly improve the accuracy of long-term prognosis assessment, and provide scientific and personalized management support for children with malignant tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a structural diagram of an electronic management system for the treatment process and follow-up of childhood malignant tumors according to the present invention; Figure 2 This is a flow chart of the electronic management method for the treatment process and follow-up of childhood malignant tumors described in the present invention. DETAILED DESCRIPTION

[0018] In order to further explain the technical means and effects adopted by the present invention to achieve the predetermined purpose of the invention, the technical scheme in the embodiment of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiment of the present invention. Obviously, the described embodiment is only a part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0019] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0020] The specific scheme of an electronic management system and method for the treatment process and follow-up of malignant tumors in children provided by the present invention is described in detail below with reference to the accompanying drawings.

[0021] See attached Figure 1 , which shows a structural diagram of an electronic management system for the treatment process and follow-up of childhood malignant tumors provided by an embodiment of the present invention, the system includes the following parts: Patient information management module, body surface area calculation module, drug dosage calculation module, cumulative dosage calculation module, efficacy evaluation module, disease-free survival rate prediction module; The patient information management module is responsible for collecting the patient's basic information and related examination data, and receiving the output data of all modules except the patient information management module and the body surface area calculation module; the patient information management module stores the output data, related examination reports and follow-up data received from each module, and displays them in the form of trend charts or reports according to the needs of specific implementation scenarios; the patient information management module is connected to the body surface area calculation module and the drug dosage calculation module through data transmission; The body surface area calculation module obtains the basic information of the patient from the patient information management module, calculates the patient's body surface area through the body surface area calculation formula and outputs it. The body surface area calculation module is connected with the drug dosage calculation module and the patient information management module by means of data transmission; The drug dosage calculation module receives the body surface area of ​​the patient output by the body surface area calculation module and the relevant examination data, such as liver function test data and heart function test data, output by the patient information management module, calculates and outputs the chemotherapy drug dosage for each cycle, and the drug dosage calculation module is connected to the patient information management module by means of data transmission; The cumulative dose calculation module receives the chemotherapy drug dose per cycle stored in the patient information management module, calculates the actual cumulative dose during the treatment process by accumulating it cycle by cycle, and outputs it. The cumulative dose calculation module is connected to the patient information management module by data transmission; The efficacy evaluation module receives the actual cumulative dose stored in the patient information management module, and calculates the specific value of each efficacy indicator in combination with the target cumulative dose and the type and number of efficacy indicators; normalizes the specific value of each efficacy indicator, and calculates and outputs the comprehensive treatment effect score according to the importance weight of each efficacy indicator. The efficacy evaluation module is connected to the patient information management module by data transmission; The disease-free survival rate prediction module obtains the actual cumulative dose, comprehensive treatment effect score and follow-up data corresponding to the current follow-up stage from the patient information management module, calculates the disease-free survival rate, and the disease-free survival rate prediction module is connected to the patient information management module by data transmission.

[0022] The follow-up stage refers to the critical stage after the end of treatment, in which the patient's health status, efficacy indicators and survival status are regularly monitored, and relevant data are collected to evaluate the treatment effect and guide subsequent management.

[0023] Follow-up data refers to patient health information collected during the follow-up phase, including efficacy indicators, cumulative doses, recurrences, and adverse events, which are used to evaluate treatment efficacy and predict survival rates.

[0024] See attached Figure 2 , which shows a flow chart of a method for electronic management of the treatment process and follow-up of childhood malignant tumors provided by an embodiment of the present invention, the method comprising the following steps: S1: Based on the basic information of the patient, the patient's body surface area is calculated; based on the standard chemotherapy drug dose set according to the patient's condition and the patient's body surface area, the chemotherapy drug dose for each cycle is calculated; the actual cumulative dose is obtained by accumulating the chemotherapy drug dose for each cycle cycle by cycle; During the treatment process, the doctor uploads the patient's basic information and related examination data, and uses expert experience to set the standard chemotherapy drug dose based on the patient's condition. The standard chemotherapy drug dose is the drug dose required per square meter of body surface area set according to treatment guidelines or specific conditions, and is used to guide treatment.

[0025] The patient's body surface area is calculated based on the patient's basic information. The basic information includes height (unit: cm), weight (unit: kg), age (unit: year), gender (1 for boys and 0 for girls) and body fat percentage (obtained by measurement, unit: percentage). The body surface area is a parameter for adjusting drug dosage, which is used to reflect the metabolic capacity and volume characteristics of the human body. Because children's metabolic rate, drug distribution and tolerance are significantly different from those of adults, by calculating the body surface area, it can be ensured that the chemotherapy drug dosage not only meets the treatment needs, but also avoids toxic side effects caused by excessive dosage or weakened efficacy caused by insufficient dosage, providing a scientific basis for treatment.

[0026] The formula for calculating body surface area is as follows: , in, is the patient's body surface area in square meters; is the body surface area calculation constant, which is used to adjust the calculation results to conform to the standard body surface area model and is set according to expert experience based on published body surface area calculation formulas (such as the DuBois body surface area formula) and clinical adjustments; is the patient's height in centimeters; is the patient's weight in kilograms; is the age correction factor, which is used to adjust the error caused by age differences in body surface area calculation. It reflects the impact of age on metabolic capacity and is adjusted based on clinical data and expert experience. is the patient's actual age, used to correct body surface area for age, in years; is the gender correction factor, which is used to adjust the impact of gender differences on the calculation results of body surface area and is adjusted based on clinical data and expert experience; is sex, which is used to adjust the effect of sex on body surface area. It is binary and assigned a value based on the sex of the patient, 1 for boys and 0 for girls; is the patient's body fat percentage (in percent), obtained through body fat measurement; It is the standard body fat percentage (in percentage), which is a reference value set based on the child's gender and age. It is derived from the normal body fat percentage range for children published in clinical medicine and nutrition research.

[0027] The body surface area calculation formula is based on the internationally accepted body surface area formula, and adds age correction factor, gender correction factor and body fat percentage, which more comprehensively considers the physiological characteristics and individual differences of children, and improves the accuracy of individualized calculations.

[0028] Furthermore, the patient's body surface area is used to calculate the chemotherapy drug dosage. Specifically, the patient's liver function and heart function test data are obtained, and combined with the standard chemotherapy drug dosage, the chemotherapy drug dosage per cycle is calculated. The chemotherapy drug dosage per cycle is the drug dosage adjusted in combination with the patient's body surface area, liver function and heart function, and is used for the actual administration of a single cycle of chemotherapy.

[0029] The formula for calculating chemotherapy drug dosage per cycle is as follows: , in, is the chemotherapy drug dose per cycle, indicating the total dose of chemotherapy drugs required per cycle, in milligrams (mg); It is the standard chemotherapy drug dose, which indicates the drug dose required per square meter of body surface area, in milligrams per square meter (mg / m²), and is set by the doctor based on treatment guidelines or specific conditions; is the patient's body surface area; It is an index operation; is the patient's actual alanine aminotransferase value (unit: U / L), which is derived from the liver function test results; is the normal alanine aminotransferase value (unit: U / L); Reflects the effect of liver function on drug metabolism; is the patient's left ventricular ejection fraction (unit: %), derived from the results of cardiac function tests; is the normal left ventricular ejection fraction (unit: %); Reflects the impact of cardiac function on drug tolerance.

[0030] The formula for calculating chemotherapy drug dosage for each cycle is based on traditional dosage calculation, with liver function and heart function added for correction to adapt to the metabolic capacity of different patients, thereby ensuring the treatment effect while reducing the risk of adverse reactions.

[0031] During the treatment process, the chemotherapy drug dosage for each cycle is recorded and accumulated cycle by cycle to calculate the actual cumulative dosage (in milligrams) during the treatment process. The actual cumulative dosage is an indicator of treatment progress and total drug exposure, which can help doctors evaluate the overall effect of chemotherapy and monitor whether there is a risk of toxicity caused by excessive drug dosage. By calculating the actual cumulative dosage, doctors can adjust the treatment plan in a timely manner to ensure that the best treatment effect is achieved while minimizing the adverse effects of the drug on the patient's health.

[0032] S2: Based on the actual cumulative dose, calculate the specific value of each efficacy indicator; calculate the comprehensive treatment effect score by standardizing the specific value of each efficacy indicator and combining the importance weights of each efficacy indicator; calculate the disease-free survival rate based on the actual cumulative dose and the comprehensive treatment effect score.

[0033] Based on the actual cumulative dose, the efficacy is quantitatively evaluated. The efficacy index calculation formula is introduced, and the ratio of the target cumulative dose to the actual cumulative dose is combined to evaluate whether the treatment has achieved the expected effect, and provide data support for the calculation of the comprehensive treatment effect score.

[0034] Efficacy index is a key parameter used to quantitatively evaluate the treatment effect, including specific indicators such as complete remission, partial remission, disease stabilization and disease progression. By analyzing the ratio of the actual cumulative dose to the target cumulative dose, the efficacy index can intuitively reflect the effectiveness and deviation of the treatment, and provide basic data for the comprehensive evaluation of the treatment effect; the comprehensive treatment effect score is a comprehensive evaluation result calculated based on the efficacy index. By assigning different weights to different efficacy indicators and performing standardized processing, the overall effect of the treatment is quantified. The higher the value of the comprehensive treatment effect score, the better the treatment effect.

[0035] The types and quantities of efficacy indicators are set according to the specific implementation scenarios. The calculation formula for each efficacy indicator is as follows: , in, It is Specific values ​​of the efficacy indicators; is the index variable of the efficacy index, used to identify the Items of efficacy indicators; It is The efficacy value of the efficacy index at the optimal dose, i.e. The ideal value of each efficacy indicator is set according to treatment guidelines or clinical experience; When reaching The ideal value of each efficacy indicator; It is a coefficient for adjusting the effect of dose deviation on efficacy, with a value range of 0 to 1. It is obtained by analyzing the correlation between dose deviation value and efficacy index and adjusting it in combination with expert experience using the Cox proportional hazard regression model. The Cox proportional hazard regression model is an existing technology and will not be described in detail here. is the actual cumulative dose in milligrams (mg); The target cumulative dose is expressed in milligrams (mg). The target cumulative dose is the ideal total dose of a drug in a treatment process set by a clinical study or a physician and is set based on individual patient conditions according to expert experience. It is the dose deviation value, which indicates the degree of deviation between the actual cumulative dose and the target cumulative dose. The larger the dose deviation value, the lower the efficacy.

[0036] After calculating the specific values ​​of each efficacy indicator, the calculation results are standardized, and combined with the importance weights of each efficacy indicator to further calculate the comprehensive treatment effect score.

[0037] The comprehensive treatment effect scoring formula is as follows: , in, It is a comprehensive treatment effect score, which is an overall score calculated based on efficacy indicators (such as complete remission, partial remission, etc.), reflecting the comprehensive effect of treatment. The higher the score, the better the treatment effect. is the number of efficacy indicators, which indicates the total number of efficacy indicators used to evaluate the treatment effect; is the index variable of the efficacy index; It is The weight of the efficacy indicator is used to reflect the The importance of each efficacy indicator in the comprehensive treatment effect score, with the sum of weights being 1, represents the degree of influence of each efficacy indicator on the treatment effect and the significance analysis results obtained based on clinical trials or retrospective studies, which are obtained after reasonable adjustment and optimization by experts according to specific treatment scenarios; It is an index operation; It is for The efficacy index values ​​after normalization of the efficacy indexes.

[0038] The comprehensive treatment effect score, combined with the normalized efficacy index value and the importance weight of the efficacy index, not only reflects the effectiveness of the current treatment, but also combines with the treatment delay time and follow-up data in the follow-up stage to dynamically predict the disease-free survival rate.

[0039] The follow-up stage refers to the key stage after the end of treatment, in which the patient's health status, efficacy indicators and survival status are regularly monitored, and relevant data are collected to evaluate the treatment effect and guide subsequent management; the treatment delay time refers to the time difference between the ideal start time of treatment and the actual implementation time of treatment; the follow-up data is the patient's health information collected during the follow-up stage, including efficacy indicators, cumulative doses, recurrence and adverse events, etc., which are used to evaluate the treatment effect and predict the survival rate; the disease-free survival rate refers to the probability that the patient does not experience disease progression or recurrence after treatment, which is used as an indicator for evaluating the treatment success rate and the patient's long-term prognosis.

[0040] The disease-free survival rate was calculated as follows: , in, is the disease-free survival rate, expressed as the time from the start of treatment to a specific follow-up time The probability that the patient does not experience disease recurrence or progression during treatment reflects the patient's survival status after treatment and the possibility of no disease progression. Indicates the follow-up time, which is the time from the start of treatment to the current observation point, determined by the time node in the follow-up record, which is set according to the specific implementation scenario (such as three months or six months after the first treatment, etc.); is the total number of follow-up stages, which means the total number of time periods from the start of treatment to the end of follow-up, and is set according to the expert experience method; is the current follow-up phase number; It is The number of events during the follow-up period is expressed as the number of adverse events that occurred during the follow-up period, such as death or disease progression; is the treatment delay impact coefficient, which indicates the degree of impact of treatment delay on disease-free survival rate. The larger the value, the more significant the negative impact on patient survival. is the treatment delay time, expressed in days, which represents the time difference between the ideal treatment time point and the actual treatment start time point, calculated based on the patient's treatment plan and actual treatment records; is the cumulative dose influence coefficient, which indicates the influence of the cumulative dose on the disease-free survival rate. The larger the value, the more significant the influence of insufficient or excessive cumulative dose on the disease-free survival rate. is the actual cumulative dose to the patient; It is The total number of patients in the follow-up period was obtained based on the follow-up data; It is the patient's comprehensive treatment effect score.

[0041] The above-mentioned treatment delay influence coefficient and cumulative dose influence coefficient adopt clinical trial data or public research data of similar patient groups, and use the Cox proportional hazard regression model to analyze the actual cumulative dose, treatment delay time and disease-free survival rate, and derive the values ​​of the treatment delay influence coefficient and the cumulative dose influence coefficient, which are obtained after reasonable adjustment and optimization by experts according to specific treatment scenarios.

[0042] The disease-free survival rate calculation formula comprehensively considers treatment delay, cumulative dose and comprehensive treatment effect score factors, and comprehensively analyzes the impact of the above factors on the patient's survival probability to reflect the patient's long-term survival status. Compared with the traditional method that only focuses on a single factor, the calculation of disease-free survival rate can accurately evaluate the treatment effect and provide doctors with a basis for prognosis evaluation.

[0043] According to specific implementation needs, key data during the treatment process (such as chemotherapy drug dosage per cycle, actual cumulative dosage, comprehensive treatment effect score and disease-free survival rate) and related examination reports are stored and presented intuitively in the form of trend charts, reports and data, providing a scientific basis for doctors to review historical data, optimize treatment strategies and formulate long-term management plans. At the same time, patients and their families can intuitively understand the progress of treatment and enhance their confidence and cooperation in treatment.

[0044] In summary, an electronic management system and method for the treatment process and follow-up of childhood malignant tumors has been completed.

[0045] The order of the embodiments of the invention is for description only and does not represent the advantages and disadvantages of the embodiments. The processes depicted in the drawings do not necessarily require the specific order or continuous order shown to achieve the desired results. In some embodiments, multitasking and parallel processing are also possible or may be advantageous.

[0046] The various embodiments in this specification are described in a progressive manner, and the same or similar parts between the various embodiments can be referenced to each other, and each embodiment focuses on the differences from other embodiments.

[0047] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that the technical solutions described in the above embodiments may still be modified, or some of the technical features may be replaced by equivalents. Such modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention, and should be included in the protection scope of the present invention.

Claims

1. A method for electronic management of the treatment process and follow-up of childhood malignant tumors, characterized in that: The following steps are involved: S1: Based on the basic information of the patient, the patient's body surface area is calculated; based on the standard chemotherapy drug dose set according to the patient's condition and the patient's body surface area, the chemotherapy drug dose for each cycle is calculated; the actual cumulative dose is obtained by accumulating the chemotherapy drug dose for each cycle cycle by cycle; S2: Based on the actual cumulative dose, calculate the specific value of each efficacy indicator; calculate the comprehensive treatment effect score by standardizing the specific value of each efficacy indicator and combining the importance weights of each efficacy indicator; calculate the disease-free survival rate based on the actual cumulative dose and the comprehensive treatment effect score.

2. The electronic management method for the treatment progress and follow-up of childhood malignant tumors according to claim 1, characterized in that: The S1 specifically includes: The age correction factor, gender correction factor and body fat percentage are introduced into the body surface area calculation formula. The specific formula is as follows: ， in, is the patient's body surface area; is the constant for calculating body surface area; is the patient's height; is the patient's weight; is the age correction factor; is the patient’s actual age; is the gender correction factor; is gender, which is assigned a value based on the patient's gender, 1 for boys and 0 for girls; is the patient's body fat percentage; It is the standard body fat percentage.

3. The electronic management method for the treatment progress and follow-up of childhood malignant tumors according to claim 2, characterized in that: The S1 specifically includes: The standard chemotherapy drug dose is set, and the patient's liver function and heart function test data are obtained. The chemotherapy drug dose for each cycle is calculated by combining the patient's body surface area.

4. The electronic management method for the treatment progress and follow-up of childhood malignant tumors according to claim 3, characterized in that: The S1 specifically includes: The formula for calculating chemotherapy drug dosage per cycle is as follows: ， in, is the chemotherapy drug dose per cycle; It is the standard chemotherapy drug dose, which indicates the drug dose required per square meter of body surface area; It is an index operation; is the patient's actual alanine aminotransferase value, derived from liver function test results; is a normal alanine aminotransferase value; Reflects the effect of liver function on drug metabolism; is the patient's left ventricular ejection fraction, derived from the results of cardiac function tests; is normal left ventricular ejection fraction; Reflects the impact of cardiac function on drug tolerance.

5. The electronic management method for the treatment progress and follow-up of childhood malignant tumors according to claim 1, characterized in that: The S1 specifically includes: Measuring treatment progress and total drug exposure through actual cumulative doses helps doctors evaluate the overall effectiveness of chemotherapy while monitoring whether there is a risk of toxicity caused by excessive drug doses; and adjusting treatment plans in a timely manner based on actual cumulative doses.

6. The electronic management method for the treatment progress and follow-up of childhood malignant tumors according to claim 1, characterized in that: The S2 specifically includes: The calculation formula of efficacy index is introduced, and the ratio of target cumulative dose to actual cumulative dose is combined to quantitatively evaluate the efficacy; the calculation formula of each efficacy index is as follows: ， in, It is Specific values ​​of the efficacy indicators; is the index variable of the efficacy index; It is The ideal value of each efficacy indicator; It is the coefficient that adjusts the effect of dose deviation on efficacy, and its value range is 0 to 1; is the actual cumulative dose; is the target cumulative dose; It indicates the degree of deviation between the actual cumulative dose and the target cumulative dose.

7. The electronic management method for the treatment progress and follow-up of childhood malignant tumors according to claim 1, characterized in that: The S2 specifically includes: The disease-free survival rate was calculated based on the comprehensive treatment effect score, combined with the treatment delay time and follow-up data corresponding to the follow-up stage.

8. The electronic management method for the treatment progress and follow-up of childhood malignant tumors according to claim 7, characterized in that: The S2 specifically includes: The disease-free survival rate was calculated as follows: ， in, is the disease-free survival rate; indicates the follow-up time; is the total number of follow-up periods; is the current follow-up phase number; Indicated in The number of adverse events that occurred during the follow-up period; is the treatment delay effect coefficient; is the treatment delay time, which represents the time difference between the ideal treatment time point and the actual treatment start time point; is the cumulative dose influence coefficient; It is The total number of patients in the follow-up period was obtained based on the follow-up data; It is the patient's comprehensive treatment effect score.

9. An electronic management system for the treatment progress and follow-up of childhood malignant tumors, applied to the electronic management method for the treatment progress and follow-up of childhood malignant tumors as claimed in any one of claims 1 to 8, characterized in that: Includes the following parts: Patient information management module, body surface area calculation module, drug dosage calculation module, cumulative dosage calculation module, efficacy evaluation module, disease-free survival rate prediction module; The patient information management module is responsible for collecting the patient's basic information and related examination data, and receiving the output data of all modules except the patient information management module and the body surface area calculation module; The patient information management module stores the output data, relevant examination reports and follow-up data received from each module and displays them in the form of trend graphs or reports; The patient information management module is connected with the body surface area calculation module and the drug dosage calculation module by means of data transmission; The body surface area calculation module obtains the basic information of the patient from the patient information management module, calculates the patient's body surface area through the body surface area calculation formula and outputs it. The body surface area calculation module is connected with the drug dosage calculation module and the patient information management module by means of data transmission; The drug dosage calculation module receives the body surface area of ​​the patient output by the body surface area calculation module and the relevant examination data output by the patient information management module, including liver function test data and heart function test data, calculates and outputs the chemotherapy drug dosage for each cycle, and the drug dosage calculation module is connected to the patient information management module by means of data transmission; The cumulative dose calculation module receives the chemotherapy drug dose per cycle stored in the patient information management module, calculates the actual cumulative dose by accumulating it cycle by cycle, and outputs it. The cumulative dose calculation module is connected to the patient information management module by data transmission; The efficacy evaluation module receives the actual cumulative dose stored in the patient information management module, and calculates the specific value of each efficacy indicator in combination with the target cumulative dose and the type and number of efficacy indicators; normalizes the specific value of each efficacy indicator, and calculates and outputs the comprehensive treatment effect score according to the importance weight of each efficacy indicator. The efficacy evaluation module is connected to the patient information management module by data transmission; The disease-free survival rate prediction module obtains the actual cumulative dose, comprehensive treatment effect score and follow-up data corresponding to the current follow-up stage from the patient information management module, calculates the disease-free survival rate, and the disease-free survival rate prediction module is connected to the patient information management module by data transmission; The follow-up phase refers to the phase after treatment, during which the patient's health status, efficacy indicators, and survival status are regularly monitored to collect relevant data to evaluate the treatment effect and guide subsequent management; Follow-up data are patient health information collected during the follow-up phase, including efficacy indicators, cumulative doses, recurrences, and adverse events.

Images